Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies-Reference-Cited by-同舟云学术

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Published:2019-10-22 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Xu-Monette Zijun Y.,Li Jianyong,Xia Yi,Crossley Beryl,Bremel Robert D.,Miao Yi,Xiao Min,Snyder Thomas,Manyam Ganiraju C.,Tan Xiaohong,Zhang Hongwei,Visco Carlo,Tzankov Alexandar,Dybkaer Karen,Bhagat Govind,Tam Wayne,You Hua,Hsi Eric D.,van Krieken J. Han,Huh Jooryung,Ponzoni Maurilio,Ferreri Andrés J. M.,Møller Michael B.,Piris Miguel A.,Winter Jane N.,Medeiros Jeffrey T.,Xu Bing,Li Yong,Kirsch Ilan,Young Ken H.

Funder

National Cancer Institute

National Cancer institute

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0730-x.pdf

Reference50 articles.

1. Kuppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol. 1997;27(6):1398–405.

2. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–6.